Metformin, an old drug, brings a new era to cancer therapy

Cancer Journal (United States)

Volumn 21, Issue 2, 2015, Pages 70-74

  He, Huan ^a   Ke, Rong ^a   Lin, Hui ^a   Ying, Ying ^a   Liu, Dan ^a   Luo, Zhijun ^b  

^a NANCHANG UNIVERSITY   (China)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer therapy; diabetes; Metformin

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

CANCER PREVENTION; CANCER STEM CELL; CANCER THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NEOPLASM; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ANIMAL; COMPLICATION; GENETICS; METABOLISM; NEOPLASMS; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84926662707     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000103     Document Type: Review

References (53)

1. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143-156.
2. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 1956;6:457-470.
3. Hainaut P, Plymoth A. Cancer as a metabolic disease. Curr Opin Oncol. 2012;24:56-57.
4. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
5. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013;45:e45.
6. Luo Z, Saha AK, Xiang X, et al. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005;26:69-76.
7. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
8. Joost HG. Diabetes and cancer: epidemiology and potential mechanisms. Diab Vasc Dis Res. 2014;11:390-394.
9. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103-1123.
10. Hall GC, Roberts CM, Boulis M, et al. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28:590-594.
11. Bailey CJ, Day C. Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. Int J Clin Pract. 2004;58: 867-876.
12. OwenMR, Doran E, Halestrap AP. Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(pt 3):607-614.
13. Zhang L, He H, Balschi JA. Metformin and phenformin activate AMPactivated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol. 2007;293:H457-H466.
14. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120:2355-2369.
15. CoughlanKA, Valentine RJ, RudermanNB, et al.AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes. 2014;7: 241-253.
16. Dilman VM, Berstein LM, OstroumovaMN, et al.Metabolic immunodepression andmetabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology. 1982;39:13-19.
17. Dilman VM, Berstein LM, Yevtushenko TP, et al. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch Geschwulstforsch. 1988; 58:175-183.
18. Dilman VM, Berstein LM, Zabezhinski MA, et al. Inhibition of DMBAinduced carcinogenesis by phenformin in the mammary gland of rats. Arch Geschwulstforsch. 1978;48:1-8.
19. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/ neu transgenic mice. Exp Gerontol. 2005;40:685-693.
20. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17-29.
21. Miranda VC, Barroso-Sousa R, Glasberg J, et al. Exploring the role ofmetformin in anticancer treatments: a systematic review. Drugs Today (Barc). 2014;50:623-640.
22. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8:e71583.
23. Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37: 207-218.
24. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297-3302.
25. Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect ofmetformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118:1202-1211.
26. Hou G, Zhang S, Zhang X, et al. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat. 2013;137:807-816.
27. Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35:299-304.
28. Chen TM, Lin CC, Huang PT, et al.Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011;26:858-865.
29. Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as firstline chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer. 2011;117:5103-5111.
30. Bodmer M, Becker C, Jick SS, et al. Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer. 2012;78:133-137.
31. Smiechowski BB, Azoulay L, Yin H, et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36:124-129.
32. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012; 12:410.
33. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008;8: 501-505.
34. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128:783-794.
35. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3:1077-1083.
36. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11:390-401.
37. Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in dietinduced insulin-resistant mice. Cell Metab. 2011;13:376-388.
38. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174.
39. Chen S, Zhu X, Lai X, et al. Combined cancer therapy with non-conventional drugs: all roads lead to AMPK. Mini Rev Med Chem. 2014;14:642-654.
40. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336:918-922.
41. Din FV, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142:1504.e3-1515.e3.
42. Groenendijk FH,MellemaWW, van der Burg E, et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer. 2015;136:1434-1444.
43. DanzigMR, Kotamarti S, Ghandour RA, et al. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis. 2015;18:63-68.
44. Wilcock C, Bailey CJ. Accumulation ofmetformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24:49-57.
45. Shackelford DB, Abt E, Gerken L, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23:143-158.
46. BuzzaiM, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745-6752.
47. Birsoy K, Possemato R, Lorbeer FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014;508: 108-112.
48. Larman TC, DePalma SR, Hadjipanayis AG, et al. Spectrum of somaticmitochondrial mutations in five cancers. Proc Natl Acad Sci U S A. 2012;109: 14087-14091.
49. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69: 7507-7511.
50. Zhao Z, Cheng X, Wang Y, et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One. 2014;9:e95884.
51. Zhang J, Shen C,Wang L, et al.Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun. 2014; 452:746-752.
52. Chou CC, Lee KH, Lai IL, et al. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res. 2014;74:4783-4795.
53. Bao B, Azmi AS, Ali S, et al.Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med. 2014;2:59.